Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mitsubishi Tanabe Pharma
Pharma
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Three Chinese obesity assets are featured in Verdiva's $410 million debut. Experts analyzed the buyout prospects of Legend and BeiGene. Plus more.
Angus Liu
Jan 10, 2025 9:00am
Merck's GLP-1 play; Astellas' AAV deal—Fierce Pharma Asia
Dec 20, 2024 8:51am
Sanofi, GSK and China reimbursement updates—Fierce Pharma Asia
Dec 6, 2024 9:00am
FDA snubs AbbVie's blockbuster-to-be Parkinson's drug
Mar 22, 2023 11:50am
Mitsubishi scores $940M from Novartis in arbitration case
Feb 17, 2023 4:40pm
Sanofi-Innovent, Astellas, AbbVie-Sosei—Fierce Pharma Asia
Aug 5, 2022 10:39am
